Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Group 1 - Xeris Biopharma reported $60.1 million in revenue for Q4 2024, a year-over-year increase of 35.4% [1] - The EPS for the same period was -$0.03, improving from -$0.10 a year ago, with a surprise of +57.14% compared to the consensus estimate of -$0.07 [1][3] - The revenue reported was a slight miss of -0.81% against the Zacks Consensus Estimate of $60.59 million [1] Group 2 - Key product revenues included Gvoke at $23.26 million, Keveyis at $11.12 million, and Recorlev at $22.61 million, with Recorlev significantly outperforming its estimate of $11.19 million [4] - Royalty, contract, and other revenues were reported at $3.10 million, exceeding the average estimate of $1.30 million [4] - Overall product revenue, net, was $57 million, slightly above the estimated $56.26 million [4] Group 3 - Xeris Biopharma's shares returned +2.7% over the past month, contrasting with the Zacks S&P 500 composite's -3.5% change [3] - The company currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near term [3]